Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability

[1]  T. Ali,et al.  Peptide aptamer targeting Aβ–PrP–Fyn axis reduces Alzheimer’s disease pathologies in 5XFAD transgenic mouse model , 2023, Cellular and Molecular Life Sciences.

[2]  C. Mummery,et al.  Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial , 2023, Nature Medicine.

[3]  L. Ittner,et al.  Treatment of epilepsy using a targeted p38γ kinase gene therapy. , 2022, Science advances.

[4]  J. Sibarita,et al.  Fyn nanoclustering requires switching to an open conformation and is enhanced by FTLD-Tau biomolecular condensates , 2022, Molecular Psychiatry.

[5]  Yiyun Huang,et al.  Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q , 2022, Science Translational Medicine.

[6]  T. Thippeswamy,et al.  Fyn-tau Ablation Modifies PTZ-Induced Seizures and Post-seizure Hallmarks of Early Epileptogenesis , 2020, Frontiers in Cellular Neuroscience.

[7]  A. Ittner,et al.  Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ , 2020, Acta Neuropathologica.

[8]  S. Strittmatter,et al.  Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy , 2020, Acta Neuropathologica Communications.

[9]  Jonathan R Roth,et al.  Alzheimer’s disease risk gene BIN1 induces Tau-dependent network hyperexcitability , 2020, bioRxiv.

[10]  L. Mucke,et al.  Tau Reduction Prevents Key Features of Autism in Mouse Models , 2020, Neuron.

[11]  Jonathan R Roth,et al.  A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity , 2019, Neurobiology of Disease.

[12]  A. Andreotti,et al.  The SH3 domains of the protein kinases ITK and LCK compete for adjacent sites on T cell–specific adapter protein , 2019, The Journal of Biological Chemistry.

[13]  Eric M Reiman,et al.  Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease , 2019, JAMA neurology.

[14]  Dongxue Wang,et al.  Systematic profiling of SH3-mediated Tau-Partner interaction network in Alzheimer's disease by integrating in silico analysis and in vitro assay. , 2019, Journal of molecular graphics & modelling.

[15]  A. Araque,et al.  Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy , 2019, Acta Neuropathologica.

[16]  S. Strittmatter,et al.  Anti‐PrPC antibody rescues cognition and synapses in transgenic alzheimer mice , 2019, Annals of clinical and translational neurology.

[17]  S. Strittmatter,et al.  Rescue of Transgenic Alzheimer’s Pathophysiology by Polymeric Cellular Prion Protein Antagonists , 2019, Cell reports.

[18]  J. Lambert,et al.  Structural Basis of Tau Interaction With BIN1 and Regulation by Tau Phosphorylation , 2018, Front. Mol. Neurosci..

[19]  H. Nygaard.  Targeting Fyn Kinase in Alzheimer’s Disease , 2018, Biological Psychiatry.

[20]  Timothy A. Miller,et al.  Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy , 2017, Science Translational Medicine.

[21]  A. Ittner.  SITE-SPECIFIC PHOSPHORYLATION OF TAU INHIBITS AMYLOID-β TOXICITY IN ALZHEIMER’S MICE , 2016, Alzheimer's & Dementia.

[22]  L. Mucke,et al.  Network abnormalities and interneuron dysfunction in Alzheimer disease , 2016, Nature Reviews Neuroscience.

[23]  C. Simmerling,et al.  ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.

[24]  E. Roberson,et al.  Seizure resistance without parkinsonism in aged mice after tau reduction , 2014, Neurobiology of Aging.

[25]  J. Wells,et al.  Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. , 2014, Chemistry & biology.

[26]  R. Bostwick,et al.  AlphaScreen HTS and Live-Cell Bioluminescence Resonance Energy Transfer (BRET) Assays for Identification of Tau–Fyn SH3 Interaction Inhibitors for Alzheimer Disease , 2014, Journal of biomolecular screening.

[27]  A. Bush,et al.  Motor and cognitive deficits in aged tau knockout mice in two background strains , 2014, Molecular Neurodegeneration.

[28]  L. Mucke,et al.  Tau Reduction Prevents Disease in a Mouse Model of Dravet Syndrome , 2014, Annals of neurology.

[29]  A. Vortmeyer,et al.  Metabotropic Glutamate Receptor 5 Is a Coreceptor for Alzheimer Aβ Oligomer Bound to Cellular Prion Protein , 2013, Neuron.

[30]  D. Holtzman,et al.  Antisense Reduction of Tau in Adult Mice Protects against Seizures , 2013, The Journal of Neuroscience.

[31]  Daniel R Roe,et al.  PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data. , 2013, Journal of chemical theory and computation.

[32]  S. Younkin,et al.  Tau Loss Attenuates Neuronal Network Hyperexcitability in Mouse and Drosophila Genetic Models of Epilepsy , 2013, The Journal of Neuroscience.

[33]  V. Laporte,et al.  Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice. , 2012, The American journal of pathology.

[34]  N. Leclerc,et al.  Interaction of Endogenous Tau Protein with Synaptic Proteins Is Regulated by N-Methyl-d-aspartate Receptor-dependent Tau Phosphorylation* , 2012, The Journal of Biological Chemistry.

[35]  A. Vortmeyer,et al.  Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons , 2012, Nature Neuroscience.

[36]  Hans-Ulrich Demuth,et al.  Prion-Like Behavior and Tau-dependent Cytotoxicity of Pyroglutamylated β-Amyloid , 2012, Nature.

[37]  W. Noble,et al.  Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau , 2011, The FEBS journal.

[38]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[39]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[40]  E. Mandelkow,et al.  Proline-directed Pseudo-phosphorylation at AT8 and PHF1 Epitopes Induces a Compaction of the Paperclip Folding of Tau and Generates a Pathological (MC-1) Conformation* , 2008, Journal of Biological Chemistry.

[41]  M. Zvelebil,et al.  Phosphorylation Regulates Tau Interactions with Src Homology 3 Domains of Phosphatidylinositol 3-Kinase, Phospholipase Cγ1, Grb2, and Src Family Kinases* , 2008, Journal of Biological Chemistry.

[42]  L. Mucke,et al.  Enkephalin Elevations Contribute to Neuronal and Behavioral Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.

[43]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[44]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[45]  F. Studier,et al.  Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.

[46]  L. Thal,et al.  Altered p59Fyn kinase expression accompanies disease progression in Alzheimer's disease: implications for its functional role , 2005, Neurobiology of Aging.

[47]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[48]  L. Mucke,et al.  Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.

[49]  Yitao Liu,et al.  Treatment of Ischemic Brain Damage by Perturbing NMDA Receptor- PSD-95 Protein Interactions , 2002, Science.

[50]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Sreenath V. Sharma,et al.  UCS15A, a novel small molecule, SH3 domain-mediated protein–protein interaction blocking drug , 2002, Oncogene.

[52]  J. Trotter,et al.  Process Outgrowth of Oligodendrocytes Is Promoted by Interaction of Fyn Kinase with the Cytoskeletal Protein Tau , 2002, The Journal of Neuroscience.

[53]  I. Campbell,et al.  The Role of the Src Homology 3-Src Homology 2 Interface in the Regulation of Src Kinases* , 2001, The Journal of Biological Chemistry.

[54]  Sreenath V. Sharma,et al.  UCS15A, a non-kinase inhibitor of Src signal transduction , 2001, Oncogene.

[55]  N. Hirokawa,et al.  Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice , 2000, Neuroscience Letters.

[56]  S. Nakanishi,et al.  PSD-95 promotes Fyn-mediated tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit NR2A. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  H. Band,et al.  Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.

[58]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  J. Wood,et al.  The protein tyrosine kinase, fyn, in Alzheimer's disease pathology , 1993, Neuroreport.

[60]  Guoqiang Dong,et al.  Overview of Protein-Protein Interactions and Small-Molecule Inhibitors Under Clinical Development , 2018 .